Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Spinal Cord Injury Therapeutics market. The report identifies the key trends shaping and driving the global Acute Spinal Cord Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Spinal Cord Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Spinal Cord Injury Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Spinal Cord Injury Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Acute Spinal Cord Injury Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Spinal Cord Injury Therapeutics therapeutics market.
• Analysis of key recent licensing and partnership agreements in Acute Spinal Cord Injury Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Acute Spinal Cord Injury Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Spinal Cord Injury Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Acute Spinal Cord Injury Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Acute SCI Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Signs and Symptoms 11
2.5 Diagnosis 11
2.6 Treatment and Management Pattern 12
2.7 Referral Pathway 13
2.8 GlobalData Pipeline Report Guidance 14

3 Acute SCI Therapeutics: Market Characterization 15
3.1 Overview 15
3.2 Acute SCI Therapeutics Market Size (2005–2010) – Global 15
3.3 Acute SCI Therapeutics Market Forecast (2010–2017) – Global 16
3.4 Acute SCI Therapeutics Market Size (2005–2010) – The US 17
3.5 Acute SCI Therapeutics Market Forecast (2010–2017) – The US 18
3.6 Acute SCI Therapeutics Market Size (2005–2010) – France 19
3.7 Acute SCI Therapeutics Market Forecast (2010–2017) – France 20
3.8 Acute SCI Therapeutics Market Size (2005–2010) – Germany 21
3.9 Acute SCI Therapeutics Market Forecast (2010-2017) – Germany 22
3.10 Acute SCI Therapeutics Market Size (2005–2010) – Italy 23
3.11 Acute SCI Therapeutics Market Forecast (2010–2017) – Italy 24
3.12 Acute SCI Therapeutics Market Size (2005–2010) – Spain 25
3.13 Acute SCI Therapeutics Market Forecast (2010–2017) – Spain 26
3.14 Acute SCI Therapeutics Market Size (2005–2010) – The UK 27
3.15 Acute SCI Therapeutics Market Forecast (2010–2017) – The UK 28
3.16 Acute SCI Therapeutics Market Size (2005–2010) – Japan 29
3.17 Acute SCI Therapeutics Market Forecast (2010–2017) – Japan 30
3.18 Drivers and Barriers for the Acute SCI Therapeutics Market 31
3.18.1 Drivers for the Acute SCI Therapeutics Market 31
3.18.2 Barriers for Acute SCI Therapeutics Market 31
3.19 Opportunity and Unmet Need Analysis 32
3.19.1 Opportunity and Unmet Need in the Acute SCI Market 32
3.20 Key Takeaway 32

4 Acute SCI Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the Acute SCI Therapeutics 34
4.3.1 Medrol 34
4.4 Key Takeaway 34

5 Acute SCI Therapeutics: Pipeline Assessment 35
5.1 Overview 35
5.2 Strategic Pipeline Assessment 35
5.3 Acute SCI Therapeutics Pipeline – Pipeline by Phases of Development 36
5.3.1 Acute SCI Therapeutics – Phase III Pipeline 36
5.3.2 Acute SCI Therapeutics –Phase II Pipeline 36
5.3.3 Acute SCI Therapeutics –Phase I Pipeline 37
5.3.4 Acute SCI Therapeutics – Preclinical Phase 37
5.3.5 Acute SCI Therapeutics – Discovery Pipeline 37
5.4 Technology Trends Analytic Framework 38
5.5 Acute SCI Therapeutics Market – Pipeline by Mechanism of Action 40
5.6 Acute SCI Therapeutics – Promising Drugs under Clinical Development 40
5.7 Molecule Profiling for Promising Drugs Under Clinical Development 41
5.7.1 Lyrica 41
5.7.2 ProCord 42
5.8 Key Takeaway 42

6 Acute SCI Therapeutics: Clinical Trials Mapping 43
6.1 Clinical Trials by Country 43
6.2 Clinical Trials by Phase 44
6.3 Clinical Trials by Trial Status 45
6.4 Top 10 Companies Participating in Therapeutics Clinical Trials 46
6.5 Prominent Sponsors 47

7 Acute SCI Therapeutics: Strategic Assessment 49
7.1 Key Events Impacting the Future Market 49
7.2 Implications for Future Market Competition 50

8 Acute SCI Therapeutics: Future Players 51
8.1 Introduction 51
8.2 Company Profiles 52
8.2.1 Pfizer 52
8.2.2 Proneuron Biotechnologies 56

9 Acute SCI Therapeuctics: Licensing and Partnership Deals 57

10 Acute SCI Therapeutics: Appendix 58
10.1 Market Definitions 58
10.2 Abbreviations 58
10.3 Research Methodology 59
10.3.1 Coverage 59
10.3.2 Secondary Research 59
10.3.3 Forecasting 60
10.4 Contact Us 63
10.5 Disclaimer 63
10.6 Bibliography 64

List of Tables

Table 1: Effects of SCI by Location 10
Table 2: Spinal Injury Impairment Scale 12
Table 3: Acute SCI Therapeutics Market, Global, Revenue, ($m), 2005–2010 15
Table 4: Acute SCI Therapeutics Market, Global, Forecast ($m), 2010–2017 16
Table 5: Acute SCI Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Table 6: Acute SCI Therapeutics Market, The US, Forecast ($m), 2010–2017 18
Table 7: Acute SCI Therapeutics Market, France, Revenue ($m), 2005–2010 19
Table 8: Acute SCI Therapeutics Market, France, Forecasts ($m), 2010–2017 20
Table 9: Acute SCI Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Table 10: Acute SCI Therapeutics Market, Germany, Forecast ($m), 2010–2017 22
Table 11: Acute SCI Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Table 12: Acute SCI Therapeutics Market, Italy, Forecast ($m), 2010–2017 24
Table 13: Acute SCI Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Table 14: Acute SCI Therapeutics Market, Spain, Forecast ($m), 2010–2017 26
Table 15: Acute SCI Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Table 16: Acute SCI Therapeutics Market, The UK, Forecast ($m), 2010–2017 28
Table 17: Acute SCI Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Table 18: Acute SCI Therapeutics Market, Japan, Forecast ($m), 2010–2017 30
Table 19: Acute SCI Therapeutics – Phase III Clinical Pipeline, 2011 36
Table 20: Acute SCI Therapeutics – Phase II Clinical Pipeline, 2011 36
Table 21: Acute SCI Therapeutics – Phase I Clinical Pipeline, 2011 37
Table 22: Acute SCI Therapeutics – Preclinical Pipeline, 2011 37
Table 23: Acute SCI Therapeutics – Discovery Pipeline, 2011 37
Table 24: Acute SCI Therapeutics – Most Promising Drugs Under Clinical Development, 2011 40
Table 25: Acute SCI Therapeutics Market, Clinical Trials by Country, 2011 43
Table 26: Acute SCI Therapeutics Market, Clinical Trials by Phase, 2011 44
Table 27: Acute SCI Therapeutics Market, Clinical Trials by Trial Status, 2011 45
Table 28: Acute SCI Therapeutics Market, Clinical Trials by Top Companies Participating in Therapeutics Clinical Trials, 2011 46
Table 29: Acute SCI Therapeutics Market – Clinical Trials by Overall Sponsors, 2011 47
Table 30: Acute SCI Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011 48
Table 31: Pfizer, CNS Pipeline, As on February 28, 2011 54
Table 32: Pfizer, SCI Pipeline, February 28, 2011 54
Table 33: Pfizer, Deals, 2009-2010 55
Table 34: NeuroHealing Pharmaceuticals – CNS Pipeline Products, 2011 56
Table 35: SCI Therapeutics Market, Global, Deals, 2007-2008 57

List of Figures

Figure 1: Spinal Cord After Injury 8
Figure 2: Acute SCI Therapeutics Market – SCI Causes 9
Figure 3: Effects of SCIs 10
Figure 4: Referral Pathway for Acute SCI 13
Figure 5: Acute SCI Therapeutics Market, Global, Revenue ($m), 2005–2010 15
Figure 6: Acute SCI Therapeutics Market, Global, Forecast ($m), 2010–2017 16
Figure 7: Acute SCI Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Figure 8: Acute SCI Therapeutics Market, The US, Forecast ($m), 2010–2017 18
Figure 9: Acute SCI Therapeutics Market, France, Revenue ($m), 2005–2010 19
Figure 10: Acute SCI Therapeutics Market, France, Forecast ($m), 2010–2017 20
Figure 11: Acute SCI Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Figure 12: Acute SCI Therapeutics Market, Germany, Forecast ($m), 2010–2017 22
Figure 13: Acute SCI Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Figure 14: Acute SCI Therapeutics Market, Italy, Forecast ($m), 2010–2017 24
Figure 15: Acute SCI Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Figure 16: Acute SCI Therapeutics Market, Spain, Forecast ($m), 2010–2017 26
Figure 17: Acute SCI Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Figure 18: Acute SCI Therapeutics Market, The UK, Forecast ($m), 2010–2017 28
Figure 19: Acute SCI Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Figure 20: Acute SCI Therapeutics Market, Japan, Forecast ($m), 2010–2017 30
Figure 21: Opportunity and Unmet Need in the Acute SCI Therapeutics Market, 2010 32
Figure 22: Strategic Competitor Assessment of the Marketed Products for Acute SCIs, 2011 33
Figure 23: Acute SCI Therapeutics Pipeline by Phase of Development, 2011 36
Figure 24: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline, 2011 38
Figure 25: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline- Description, 2011 39
Figure 26: Acute SCI Therapeutics, Pipeline by Mechanism of Action, 2011 40
Figure 27: Acute SCI Therapeutics Market, Clinical Trials by Country, 2011 43
Figure 28: Acute SCI Therapeutics Market – Clinical Pipeline by Phase, 2011 44
Figure 29: Acute SCI Therapeutics Market – Clinical Trials by Trial Status, 2011 45
Figure 30: Acute SCI Therapeutics Market – Clinical Trials by Top Companies Participating in Therapeutics Clinical Trials, 2011 46
Figure 31: Acute SCI Therapeutics Market – Clinical Trials by Overall Sponsors, 2011 47
Figure 32: Acute SCI Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011 48
Figure 33: Acute SCI Therapeutics Market, Drivers and Barriers, 2011 49
Figure 34:Implications for Future Market Competition in the Acute SCI Therapeutics Market, 2011 50
Figure 35: Acute SCI Therapeutics Market – Clinical Pipeline by Company, 2011 51
Figure 36: GlobalData Market Forecasting Model 62